Highest-materiality recent filing
Scienture CFO Eric Sherb resigns; co-CEO Narasimhan Mani named interim CFO
Eric Sherb resigned as CFO effective May 26, 2026; cited personal reasons, no disagreement with management or board.
SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt
Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.
Scienture Holdings posts revised investor presentation; no specific details provided in filing
Filed an 8-K announcing a revised investor presentation posted on its website.
Scienture Holdings secures $11M secured note financing from Streeterville Capital
$8.42M A-1 Note (net $8M after $400K OID) and $3M B Note issued; total proceeds $11M.
Scienture Holdings posts revised investor presentation; no material new details disclosed
Revised investor presentation posted on www.scientureholdings.com for use at analyst and investor meetings.
Scienture shareholders reject 20x authorized share increase; approve reverse split and equity plan
Proposal to boost authorized common shares from 100M to 2B and preferred from 10M to 200M was rejected (5.3M for, 5.5M against).
Scienture increases at-the-market equity facility to $150M via Maxim Group
Maximum aggregate offering price under ATM agreement raised to $150 million; entire amount remains available as of Nov 7, 2025.
Scienture Holdings increases ATM offering capacity by $9.6M
Filed prospectus supplement to sell up to $9,592,009 in common stock under ATM facility.
Scienture Holdings amends co-CEO employment agreements, increases base salaries and severance
Dr. Mani's base salary raised from $325,000 to $400,000; Dr. Hariharan's from $175,000 to $400,000.
Scienture receives Nasdaq delisting notice for bid price below $1.00
Notice received Oct 14, 2025 for non-compliance with Nasdaq Listing Rule 5450(a)(1).
Scienture refinances $2.7M NVK loan with $3.9M Streeterville note, issues 250K shares
Entered $3,911,111 senior secured note (net $3.5M) with Streeterville Capital; 9% interest, 7-month term.
Scienture Holdings reduces stockholder quorum requirement to one-third
Board voted Oct 1, 2025 to amend Bylaws, lowering quorum from majority to one-third of voting stock.
Scienture Holdings converts $559K debentures to equity at $2.4861/share, terminates Arena debt
Conversion price of 10% OID secured debentures amended to $2.4861 per share.
Scienture Holdings enters $9.2M ATM equity distribution agreement with Maxim Group
Total gross sales price up to $9.2M under shelf registration (Form S-3).
Scienture raises ~$3.9M via registered direct offering of 3.225M shares at $1.20/share
Offering of 3,225,000 shares at $1.20/share for gross proceeds of ~$3.9M; closed August 15, 2025.
Scienture raises up to $3M in bridge funding; secures $1.2M initially
Board approved capital raise of up to $3M; Company sold 754,716 shares at $1.59 per share.
Scienture Holdings enters indemnification agreements with five directors/officers
Agreements with Mayur Doshi, Donald Fell, Shankar Hariharan, Subbarao Jayanthi, and Narasimhan Mani.
Scienture Holdings CEO and President resign; Nasdaq bid-price deficiency received
CEO Suren Ajjarapu and Chairman resigned May 16; President Prashant Patel resigned May 20, both no disputes.
Scienture divests IPS and Bonum to Tollo for $5M note; focuses on Specialty Pharma
Total consideration is $5M in a promissory note bearing interest at prime rate, maturing June 30, 2030.
Scienture receives FDA approval for Arbli (losartan oral suspension); launch planned Q3 2025
FDA approves SCN-102 as Arbli (losartan potassium oral suspension), first liquid ready-to-use losartan in US.
Scienture appoints Eric Sherb as CFO; Patel steps down as interim principal financial officer
Eric Sherb appointed CFO effective March 13, 2025; he served as accounting consultant since 2023.
Scienture gets exclusive US rights to commercialize REZENOPY naloxone nasal spray from Kindeva
Exclusive 10-year US license to commercialize REZENOPY (naloxone HCl 10mg) from Kindeva; term expires 10 yrs from first commercial sale.
Two directors resign from Scienture Holdings; board reduced to 5 members
Narasimhan Mani resigned as director on Jan 15, 2025; Prashant Patel resigned on Jan 16, 2025.
Scienture receives Nasdaq delisting notice for missing 2024 annual meeting; corrects prior 8-K
Received Nasdaq notice on Jan 3, 2025 for non-compliance with Listing Rule 5620(a) due to no 2024 annual meeting.
Scienture secures $3M first tranche of convertible debentures and $50M ELOC
First closing on Nov 25, 2024: $3,333,333 principal of 10% OID secured convertible debentures issued for $3,000,000.
Scienture Holdings converts all Series X Preferred Stock into 6.8M common shares
6,826,713 common shares issued upon conversion of all outstanding Series X Preferred Stock on Sep 20, 2024.
Scienture Holdings files investor presentation; no material new facts disclosed
Investor presentation dated October 4, 2024, furnished as Exhibit 99.1.
TRxADE Health renamed Scienture Holdings; ticker changes to SCNX on Nasdaq
Name change effective September 23, 2024; new CUSIP 80880X104.
TRxADE HEALTH completes merger with Scienture; issues Series X preferred convertible to common
Closed merger with Scienture Inc. on July 25; Scienture holders get 291,555 common shares (19.99% of pre-deal float) and 6,826,713 Series X non-voting convertible preferred shares.
TRxADE Health declares special $1.50/share dividend from asset sale proceeds
Special cash dividend of $1.50 per share of common stock declared by board.
TRxADE Health appoints Subbarao Jayanthi to board, Narasimhan Mani resigns
Subbarao Jayanthi appointed to TRxADE Health board on June 17, 2024.
Received Nasdaq notice on May 23, 2024 for failing to timely file Q1 10-Q; must submit compliance plan by July 22, 2024.
TRxADE Health still unable to file Q1 10-Q, faces potential Nasdaq compliance issue
Filed Form 12b-25 on May 15, but still unable to file Q1 10-Q for period ended March 31, 2024.
TRxADE Health declares $8 special dividend from asset sale proceeds
Special cash dividend of $8.00 per share declared; payable March 22, 2024 to holders of record March 18, 2024.
TRxADE Health sells Trxade marketplace assets to Micro Merchant Systems for $22.5M
Base purchase price $22.5M cash at closing; additional $7.5M earnout if MMS collects ≥$1.6M from third parties within 4 months.
TRxADE Health files late Q3 2023 10-Q, says regains Nasdaq compliance
Filed Form 10-Q for period ended Sep 30, 2023, which was overdue since Nov 2023.
Superlatus failed to meet post-closing condition to acquire Prestige Farms, leading to material breach.
TRxADE HEALTH receives Nasdaq delinquency notice for late 10-Q filing
Received Nasdaq notice on Nov 21, 2023 for non-compliance with Listing Rule 5250(c)(1).
TRxADE HEALTH delays Q3 10-Q filing; expects Nasdaq non-compliance notice
Company will not file Q3 2023 10-Q within the five-day grace period under Rule 12b-25.
Superlatus appoints Rainforest as exclusive distributor in North Atlantic, Northeast, Midwest, Mid-Atlantic regions for CPG brands like Coolhaus and Spero.
TRxADE HEALTH raises $290k via private placement of Series C Preferred and warrants
Gross proceeds of $290,000 from sale of 290 shares of Series C Convertible Preferred at $1,000/share to Hudson Global Ventures.
TRxADE HEALTH subsidiary Superlatus acquires Spero Foods assets for cash
Superlatus (wholly owned by TRxADE HEALTH) acquired all assets of Spero Foods on Oct 2, 2023, for cash.
TRxADE Health dismisses MaloneBailey as auditor, engages CM3 Advisory
Dismissed MaloneBailey, LLP as independent auditor effective Sept 14, 2023; audit committee approved.
Superlatus (TRxADE subsidiary) to launch pulse-based protein snacks under Brave Robot in early 2024
Dr. Gino Bortone, inventor of Twisted Cheetos, named CTO of Superlatus.
TRxADE HEALTH subsidiary buys four consumer brand trademarks for $1.25M
Superlatus (TRxADE subsidiary) acquires trademarks for Coolhaus, Brave Robot, Modern Kitchen, California Performance Co. from Perfect Day and The Urgent Company for $1,250,000.
TRxADE closes Superlatus acquisition, regains Nasdaq compliance
Acquired Superlatus; shareholders received 136,441 common shares (19.99% stake) and 306,855 Series B Preferred (100:1 conversion).
TRxADE Health amends merger with Superlatus; adds share rights for existing holders
Superlatus shareholders get 30,821,941 shares at $7.30: 136,441 common (19.99% post-merger) and 306,855 Series B convertible preferred (100:1).
TRxADE Health regains Nasdaq minimum bid price compliance; matter closed
Received Nasdaq Compliance Letter on July 7, 2023 confirming regained compliance with Bid Price Requirement (Rule 5550(a)(2)).
TRxADE Health to acquire Superlatus, shifting to food & snack industry; new shares to be issued.
Superlatus shareholders receive 173,463 MEDS shares (136,436 common, 37,027 Series B preferred convertible at 100:1).
TRxADE Health receives Nasdaq delisting notice for insufficient public shares
Nasdaq notified TRxADE on June 23, 2023, that it had ~310,057 publicly held shares, below the 500,000 minimum.
the Company appointed Dr. Narasimhan Mani (age 51) to serve as the Company’s Interim Chief Financial Officer ("Interim CFO") effective as of May 26, 2026.
On May 26, 2026, Eric Sherb, the Chief Financial Officer ("CFO") of Scienture Holdings, Inc. (the "Company"), formally resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute or disagreement with the Company, its management, or its board of directors.
On May 16, 2025, as part of a planned leadership succession, Suren Ajjarapu advised the Company that he was resigning from his position as the Company’s Chief Executive Officer and Chairman of the Board effective immediately.
the Company’s board of directors appointed Dr. Narasimhan Mani, age 50, and Dr. Shankar Hariharan, age 68, to serve as co-Chief Executive Officers of the Company effective as of May 20, 2025.
As part of the planned leadership transition, Prashant Patel also advised the Company that he was resigning from his position as the Company’s President and Chief Operating Officer, effective as of May 20, 2025.
The board of directors also appointed Dr. Mani to serve as a director on the Company’s board of directors to fill the vacancy created as a result of Mr. Ajjarapu’s resignation and appointed Dr. Hariharan to the position of Executive Chairman of the Company’s board of directors, each effective as of May 20, 2025.
Mr. Patel notified the Company’s Board of Directors of his intention to resign his position as Interim Principal Financial/Accounting Officer effective as of the Effective Date.
On March 13, 2025, the Board of Directors of Scienture Holdings, Inc. (the “Company”) appointed Eric Sherb to serve as the Company’s Chief Financial Officer effective as of March 13, 2025
On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of Scienture Holdings, Inc.
On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of Scienture Holdings, Inc.
on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.
on July 25, 2024, the Company’s Board appointed Shankar Hariharan and Narasimhan Mani to the Board.
Max materiality 0.90 · Median 0.65 · Most common event other_material